A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure

Dargie, H., Hildebrandt, P., Riegger, G., McMurray, J. , McMorn, S., Roberts, J., Zambanini, A. and Wilding, J. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. Journal of the American College of Cardiology, 49, pp. 1696-1704. (doi:10.1016/j.jacc.2006.10.077)

Full text not currently available from Enlighten.


Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Dargie, H., Hildebrandt, P., Riegger, G., McMurray, J., McMorn, S., Roberts, J., Zambanini, A., and Wilding, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences
Journal Name:Journal of the American College of Cardiology

University Staff: Request a correction | Enlighten Editors: Update this record